Pacific Biosciences of California Inc PACB.OQ PACB.O is expected to show a rise in quarterly revenue when it reports results on August 7 for the period ending June 30 2025
The Menlo Park California-based company is expected to report a 2.5% increase in revenue to $36.919 million from $36.01 million a year ago, according to the mean estimate from 9 analysts, based on LSEG data.The company's guidance on May 8 2025, for the period ended June 30, was for revenue of $37.153 million.
LSEG's mean analyst estimate for Pacific Biosciences of California Inc is for a loss of 17 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 8 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Pacific Biosciences of California Inc is $1.80, about 22.8% above its last closing price of $1.39
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -0.19 | -0.19 | -1.44 | Missed | -661.9 |
Dec. 31 2025 | -0.21 | -0.21 | -0.49 | Missed | -138.6 |
Sep. 30 2024 | -0.24 | -0.22 | -0.22 | Met | 2 |
Jun. 30 2024 | -0.24 | -0.23 | -0.64 | Missed | -175.1 |
Mar. 31 2024 | -0.28 | -0.28 | -0.29 | Missed | -5.3 |
Dec. 31 2023 | -0.29 | -0.29 | -0.31 | Missed | -8.7 |
Sep. 30 2023 | -0.34 | -0.33 | -0.26 | Beat | 20.8 |
Jun. 30 2023 | -0.32 | -0.32 | -0.28 | Beat | 12.7 |
This summary was machine generated August 5 at 22:12 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)